What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Active ingredient for drug included. Blind identification by package number”In the company’s words, NCT07032649 on ClinicalTrials.gov
- Tested for
- HSV
- Main trialPhase 2
- “Here's a clear, concise, and accurate \*\*brief summary\*\* suitable for your ClinicalTrials.gov PRS submission: * Brief Summary: This randomized, double-blind, placebo-controlled clinical trial evaluates the effectiveness of topical Benzoyl Peroxide (10%) in preventing recurrent oral lesions caused by Herpes Simplex Virus Type 1 (HSV-1). Participants who experience frequent HSV-1 outbreaks will be randomly assigned to either Benzoyl Peroxide or placebo treatment. The trial will be conducted via telehealth visits, with treatment provided remotely. The primary objective is to determine…”In the company’s words, NCT07032649 on ClinicalTrials.gov
Other drugs for HSV
- MRNA-1647Moderna · Phase 2
- UB-621UBP Greater China (Shanghai) Co., Ltd · Phase 2
- Recombinant Herpes Zoster VaccineChangchun BCHT Biotechnology Co. · Phase 1
- BD111Shanghai BDgene Co., Ltd. · Phase 1
- 2LHERPLabo'Life · Marketed (Phase 4 trial)
Coming up1
- Jan 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | Jan 2027 | Evaluating Benzoyl Peroxide for Preventing Recurrence of HSV-1 Outbreaks With Rescue Crossover Option |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026